verapamil has been researched along with Idiopathic Parkinson Disease in 6 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The cause of Parkinson's disease (PD) is unknown." | 1.35 | Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. ( Bartels, AL; Lammertsma, AA; Leenders, KL; Lubberink, M; Luurtsema, G; van Berckel, BN, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Z | 1 |
| Wu, J | 1 |
| Yang, X | 1 |
| Cai, P | 1 |
| Liu, Q | 1 |
| Wang, KDG | 1 |
| Kong, L | 1 |
| Wang, X | 1 |
| Kortekaas, R | 2 |
| Leenders, KL | 3 |
| van Oostrom, JC | 2 |
| Vaalburg, W | 1 |
| Bart, J | 1 |
| Willemsen, AT | 2 |
| Hendrikse, NH | 1 |
| Bartels, AL | 2 |
| de Jong, BM | 1 |
| de Vries, R | 1 |
| de Klerk, O | 1 |
| Portman, A | 1 |
| van Berckel, BN | 1 |
| Lubberink, M | 1 |
| Luurtsema, G | 1 |
| Lammertsma, AA | 1 |
| Sen, AP | 1 |
| Boksa, P | 1 |
| Quirion, R | 1 |
| García-Albea, E | 1 |
| Jiménez-Jiménez, FJ | 1 |
| Ayuso-Peralta, L | 1 |
| Cabrera-Valdivia, F | 1 |
| Vaquero, A | 1 |
| Tejeiro, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled Trial of Allogeneic Bone Marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease[NCT04506073] | Phase 2 | 45 participants (Actual) | Interventional | 2020-11-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for verapamil and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
Topics: Animals; Apoptosis; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Mice; Mice, Inbred S | 2016 |
Blood-brain barrier dysfunction in parkinsonian midbrain in vivo.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Female; Humans; | 2005 |
Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain Mapping; C | 2008 |
Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease.
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Calcium C | 2008 |
Brain calcium channel related dihydropyridine and phenylalkylamine binding sites in Alzheimer's, Parkinson's and Huntington's diseases.
Topics: Aged; Alzheimer Disease; Autopsy; Binding Sites; Brain; Calcium; Calcium Channels; Dihydropyridines; | 1993 |
Parkinsonism unmasked by verapamil.
Topics: Antiparkinson Agents; Humans; Male; Middle Aged; Parkinson Disease; Verapamil | 1993 |